FDA Approves Trutakna for Proteinuria in Primary IgA Nephropathy
The FDA has approved Trutakna (atacicept-vymj) for reducing proteinuria in adults with primary IgA nephropathy.
Therapeutic Area
Therapeutic area intelligence for Immunoglobulin A Nephropathy with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.